Metropolis Health Apr-Jun consol business revenue seen rising around 23% YoY
This story was originally published at 21:16 IST on 4 July 2025
Register to read our real-time news.Informist, Friday, Jul. 4, 2025
Please click here to read all liners published on this story
--Metropolis Health: Apr-Jun consol revenue seen up 23% on year
--Metropolis Health: Apr-Jun consol specialty sales seen up about 35% on yr
--Metropolis Health: Healthcare industry saw surprising slowdown Jan-Mar
--Metropolis Health:Healthcare industry return to normalised activity Apr-Jun
--Metropolis Health: Believe co has ability to grow well organically
--Metropolis Health:Integration of recent acquisitions progressing as planned
MUMBAI – Metropolis Healthcare Ltd. Friday said its consolidated revenue for the June quarter is expected to have grown around 23% on year. This is including revenue from its recent acquisitions of Core Diagnostics, Dr. Ahuja's Pathology and Imaging Centre, and Scientific Pathology. Excluding this, the company's revenue for the quarter is expected to have grown around 13% on year, driven by an increase in patient and test volumes, a favourable shift in product mix, and improved realisations.
Post acquisition, Core Diagnostics moved from breakeven position in the March quarter to a single-digit positive margin trajectory, while Dr. Ahuja's Pathology and Imaging Centre, Scientific Pathology, outperformed the company average on margin performance, Metropolis Healthcare said. Further, the company said that integration of its recent acquisitions is progressing as planned.
The company's consolidated speciality sales is seen to have risen over 35% on year in the latest quarter on account of consolidation of Core Diagnostics, which is largely high-end specialised oncology testing, Metropolis Healthcare said. On a standalone basis, revenue from speciality segments is seen up 15% on year in the quarter. Revenue from the company's business-to-consumer segment is expected to have grown around 15% on year and those from TruHealth Wellness grew around 20%.
The company's earnings before interest, taxes, depreciation, and amortisation for the June quarter are expected to have improved sequentially on account of increased throughput, operational efficiencies and operating leverage. On a year-on-year basis, the EBITDA remained flat. Its consolidated EBITDA margin is expected to be slightly lower due to the consolidation of Core Diagnostics.
The healthcare industry experienced a surprising slowdown in the March quarter, the company said, adding that the industry returned to normalised activity in the June quarter. "Competition dynamics remains unchanged, and we continue to believe that Metropolis has the ability to keep growing well organically on the back of patients who need quality results for critical illness," the company said.
Metropolis Health reported a consolidated net profit of INR 291.42 million for the March quarter on consolidated revenue of INR 3.45 billion. On Friday, shares of the company closed over 2% higher at INR 1,773.30 on the National Stock Exchange. End
Reported by Arya S. Biju
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
